Tanvex BioPharma, Inc.
TWSE:6541.TW
62.3 (TWD) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities: | |||||||||||
Net Income
| -2,137.101 | -1,641.107 | -1,543.189 | -2,104.212 | -2,274.201 | -1,893.838 | -1,409.775 | -1,244.42 | -835.23 | -472.461 | -299.008 |
Depreciation & Amortization
| 324.833 | 281.559 | 243.582 | 220.407 | 215.964 | 142.768 | 132.705 | 117.575 | 67.382 | 40.176 | 23.317 |
Deferred Income Tax
| -920.805 | 0 | -41.751 | 0.967 | 61.322 | 38.12 | 51.187 | 13.833 | 4.752 | -4.727 | 0.083 |
Stock Based Compensation
| 326.605 | 67.547 | 52.946 | 80.356 | 155.716 | 164.308 | 172.083 | 136.482 | 42.251 | 18.714 | 1.773 |
Change In Working Capital
| 39.991 | -49.028 | -51.075 | 14.942 | -10.242 | -7.251 | -136.577 | 152.964 | 34.268 | -23.597 | 27.033 |
Accounts Receivables
| -7.09 | 0.125 | -0.974 | -0.723 | -0.883 | -0.213 | 3.725 | -4.714 | -0.182 | 0.447 | -4.571 |
Inventory
| 62.556 | -80.51 | -40.249 | 2.121 | -23.625 | -28.578 | 0 | 0 | 0 | 0 | 0 |
Accounts Payables
| 0 | -0.125 | 0.974 | 0.723 | 0.883 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Working Capital
| -15.475 | 31.482 | -10.826 | 12.821 | 13.383 | 21.327 | -139.763 | 155.744 | 34.988 | -1.618 | -2.064 |
Other Non Cash Items
| 932.668 | 7.182 | -47.534 | -0.085 | -47.219 | -49.992 | -21.639 | -9.86 | 2.382 | 7.722 | 6.945 |
Operating Cash Flow
| -1,433.809 | -1,333.847 | -1,387.021 | -1,787.625 | -1,898.66 | -1,605.885 | -1,212.016 | -833.426 | -684.195 | -434.173 | -239.857 |
Investing Activities: | |||||||||||
Investments In Property Plant And Equipment
| -89.905 | -96.079 | -30.346 | -67.495 | -93.602 | -108.756 | -116.596 | -248.562 | -373.47 | -156.062 | -47.477 |
Acquisitions Net
| 6.334 | 1.815 | 6.178 | 0.17 | 0 | 3.406 | 2.756 | 4.239 | 0.302 | 0 | -532.259 |
Purchases Of Investments
| -201.48 | 203.564 | 15.01 | -193.87 | 0 | -2,179.247 | 0 | -1,613.787 | -21.076 | 0 | 0 |
Sales Maturities Of Investments
| 201.48 | -203.564 | -15.01 | -0.17 | 1,915.18 | 1,375.434 | 455.225 | 0 | 0 | 2.5 | 0 |
Other Investing Activites
| -18.568 | -3.088 | -0.514 | 18.068 | -2.296 | -3.277 | 1.205 | -1.065 | -20.774 | 0.523 | -8.124 |
Investing Cash Flow
| -83.571 | -97.352 | -24.682 | -243.297 | 1,819.282 | -912.44 | 339.834 | -1,863.414 | -394.244 | -153.039 | -55.601 |
Financing Activities: | |||||||||||
Debt Repayment
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Common Stock Issued
| 1,207.21 | 7.235 | 1,690.429 | 1,703.38 | 982.335 | 2,145.638 | 1,663.838 | 3,342.346 | 1,608.937 | 860.326 | 1,364.782 |
Common Stock Repurchased
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Dividends Paid
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing Activities
| -127.668 | -123.29 | 1,597.317 | 121.973 | 914.155 | 2,145.638 | 1,663.838 | 3,342.346 | 1,608.937 | -243.362 | -895.23 |
Financing Cash Flow
| 1,079.542 | -123.29 | 1,597.317 | 1,730.487 | 914.155 | 2,145.638 | 1,663.838 | 3,342.346 | 1,608.937 | 616.964 | 469.552 |
Other Information: | |||||||||||
Effect Of Forex Changes On Cash
| 32.357 | 117.745 | -31.245 | -58.408 | -38.031 | -6.679 | -83.244 | -102.072 | 24.522 | 4.936 | -5.577 |
Net Change In Cash
| -405.481 | -1,436.744 | 154.369 | -358.843 | 796.746 | -379.366 | 708.412 | 543.434 | 555.02 | 34.688 | 168.517 |
Cash At End Of Period
| 380.752 | 786.233 | 2,222.977 | 2,068.608 | 2,427.451 | 1,630.705 | 2,010.071 | 1,301.659 | 758.225 | 203.205 | 168.517 |